Physician profile
Mark J Benjamin
NPI 1366433138
$115,889.44
in general payments reported to CMS, 2019-2025
28 companies · $521 in 2025
The $521 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $704 · 2020: $190 · 2021: $725 · 2022: $2,108 · 2023: $767 · 2024: $111K · 2025: $521.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Debt Forgiveness: $110K · Food and Beverage: $2,003.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Debt Forgiveness | $110,160.00 |
| Food and Beverage | $2,003.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optos, INC. | $110,160.00 | 2024 | Panoramic Ophthalmoscope |
| Alcon Vision LLC | $2,821.32 | 2019-2025 | Clareon, Hydrus Microstent, Ngenuity |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $503.56 | 2019-2021 | |
| Biotissue Holdings INC. | $372.57 | 2019-2024 | |
| Bausch & Lomb Americas INC. | $323.30 | 2022-2024 | Vyzulta, Envista Mx60 Iol |
| Thea Pharma INC. | $270.64 | 2022-2025 | Iyuzeh |
| Abbvie INC. | $192.15 | 2022-2023 | Durysta |
| Dompe US, INC. | $172.49 | 2021-2025 | Oxervate |
| Carl Zeiss Meditec, INC. | $163.82 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $153.50 | 2020-2022 | |
| Sight Sciences, INC. | $91.74 | 2019-2024 | Omni Surgical System, Tearcare System |
| Allergan, INC. | $88.34 | 2021-2022 | |
| Sun Pharmaceutical Industries INC. | $85.48 | 2019-2020 | |
| Eyevance Pharmaceuticals LLC | $75.59 | 2020-2021 | |
| Glaukos Corporation | $74.17 | 2024-2025 | Istent Infinite, Idosetr, Istent Trabecular Micro-Bypass System Model Is3 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $73.00 | 2019-2023 | |
| Amgen INC. | $52.43 | 2024-2025 | Tepezza |
| Tarsus Pharmaceuticals, INC. | $47.47 | 2024-2025 | Xdemvy |
| Shire North American Group INC | $28.50 | 2019 | |
| Vantage Technology LLC | $19.77 | 2022 | |
| Ocular Therapeutix, INC. | $18.64 | 2025 | Dextenza |
| New World Medical,INC. | $17.58 | 2024 | Clearpath, Streamline, Kahook Dual Blade |
| Johnson & Johnson Vision Care, INC. | $17.02 | 2019 | |
| Apellis Pharmaceuticals, INC. | $15.72 | 2025 | Syfovre |
| Rxsight INC | $13.92 | 2022 | |
| Horizon Therapeutics Plc | $13.33 | 2023 | Tepezza |
| Akorn, INC. | $12.67 | 2020 | |
| Quidel Corporation | $10.72 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Benjamin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.